In comparison to the entire control group, the median Ki67 index was higher (30% vs. 20%, P = 0.008), more patients had ENSAT tumour Stages III and IV, and more patients were treated with adjuvant mitotane in the platinum-based chemotherapy group. The gene discussed is MKI67; the disease is neoplasm.